People · Operator

TOM ALBRIGHT

Named in public records as an officer, director or promoter · active 2016–2018 · Biotechnology

1
Companies
3
Filings
$36.0M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Bonti, Inc.BiotechnologySeries B$36.0M$613.7M2016
Operator network

TOM ALBRIGHT at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Wajdie Ahmad · 3 companies · 1 sharedWajdie AhmadDavid Ramsay · 2 companies · 1 sharedDavid RamsayDENNIS HUANG · 2 companies · 1 sharedDENNIS HUANGFauad Hasan · 2 companies · 1 sharedFauad HasanJonathan Lim, M.D. · 2 companies · 1 sharedJonathan Lim, M.D.ALEXEY KONOV, Ph.D. · 1 companies · 1 sharedALEXEY KONOV, Ph.…David Barry Ramsay · 1 companies · 1 sharedDavid Barry RamsayDennis Barry Huang · 1 companies · 1 sharedDennis Barry HuangFauad Barry Hasan · 1 companies · 1 sharedFauad Barry HasanKenton Barry Abel · 1 companies · 1 sharedKenton Barry AbelLeonard Barry Brandt · 1 companies · 1 sharedLeonard Barry Bra…Michael Barry Jarpe · 1 companies · 1 sharedMichael Barry Jar…MICHAEL JARPE · 1 companies · 1 sharedMICHAEL JARPEWajdie Barry Ahmad · 1 companies · 1 sharedWajdie Barry AhmadBonti, Inc. · $36.0M raisedBonti, Inc.TOM ALBRIGHTTA
TOM ALBRIGHT Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside TOM ALBRIGHT on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Wajdie Ahmad13
Jonathan Lim, M.D.12
David Ramsay12
Fauad Hasan12
DENNIS HUANG12
Dennis Barry Huang11
Leonard Barry Brandt11
ALEXEY KONOV, Ph.D.11
Wajdie Barry Ahmad11
MICHAEL JARPE11
David Barry Ramsay11
Michael Barry Jarpe11
Fauad Barry Hasan11
Kenton Barry Abel11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.